|
|
Article: Strong Ph III data for Wyeth's desvenlafaxine.(investigational drug for major depressive disorder)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- June 5, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The USA's Wyeth Pharmaceuticals presented Phase III data and results from other studies concerning its investigational drug for major depressive disorder, desvenlafaxine (DVS-233), a novel serotonin-norepinephrine reuptake inhibitor at the 2006 American Psychiatric Association Annual Meeting in Toronto, Canada, which showed significant reduction in Hamilton Depression Rating ...